How Biogen Inc. Makes Most of Its Money
Biogen (NASDAQ: BIIB) recorded $2.38 billion in product revenue in the first quarter -- a nice haul for a large biotech -- but 40% of its sales came from its top-selling multiple-sclerosis drug Tecfidera.
Drug
First-Quarter 2017 Sales
Source: Fool.com
Gilead Sciences Inc Stock
€77.06
0.640%
Gilead Sciences Inc is currently one of the favorites of our community with 11 Buy predictions and no Sell predictions.
With a target price of 85 € there is a slightly positive potential of 10.3% for Gilead Sciences Inc compared to the current price of 77.06 €.
